Suven Life Sciences Limited, a clinical-stage biopharmaceutical company developing novel therapies for Central Nervous System (CNS) disorders, has announced a major milestone in its ongoing Phase-2b clinical trial of Ropanicant. The company confirmed that the study has achieved full patient enrollment ahead of schedule, marking a significant step forward in its pursuit of a new treatment option for Major Depressive Disorder (MDD).
Ropanicant is a nicotinic α4β2 receptor antagonist being investigated for its potential to address depressive symptoms through a differentiated mechanism of action. The Phase-2b study, conducted entirely in the United States, is designed as a randomized, double-blind, placebo-controlled trial involving around 195 patients across 35 clinical sites. Each participant will undergo six weeks of treatment, during which the efficacy and safety of Ropanicant will be assessed. The study’s primary endpoint focuses on improvements in depressive symptoms measured by the Montgomery–Åsberg Depression Rating Scale (MADRS). The trial is registered under ClinicalTrials.gov with Identifier NCT06836063.
Suven revealed that patient enrollment was completed in less than six months since the study began, achieving the full target of 195 patients more than two months earlier than expected. This accelerated pace highlights strong investigator engagement and enthusiasm among participating patients, offering encouraging momentum as the trial progresses into its next phase.
The company also noted that safety and tolerability continue to be monitored in real time, and no significant concerns have been identified so far. With the enrollment milestone now crossed, the study moves closer to delivering its key outcomes.
Suven Life Sciences expects topline efficacy and safety results from the Ropanicant Phase-2b trial by May 2026, a timeline that could shape the next steps for the company’s clinical development plans in depression treatment.
